The pandemic has continued to widen existing health and healthcare disparities. Attainment of health equity looms large and is arguably one of the most pressing priorities for life sciences. Social and economic vulnerabilities have been laid bare, and companies previously ambivalent now see this as a moral and business imperative.
Health Equity has implications in medicine/vaccine discovery, development and commercialization, including: identifying at-risk patients for earlier interventions, designing equitable and effective decentralized clinical trials, leveraging real world evidence to broaden patient access, and designing and configuring medical devices appropriately for all populations. What will be the impact of Health Equity for priority areas such as genomics and personalized medicine, as well as preventative medicine?
Addressing health equity requires a deep understanding of the patient/person in order to make better data-driven decisions to drive better outcomes. Adding to this challenge comes the complexity of data privacy, country regulations, and consumer protection; especially difficult to manage across EMEA.
Led by Impatient Health, we invite thought leaders to explore how partnerships should evolve to advance health equity, diving deeper into opportunities and the subthemes of structural and social determinants of health; AI/ML for healthcare; sensing and behavioural health; equitable and inclusive content; design and participatory research; and privacy, trust, and safety.
Hosted by Paul Simms